Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025JAC-Antimicrobial ResistanceOpen Access

The global epidemiology of carbapenem-resistant Acinetobacter baumannii

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAngelique E BoutzoukasYDYohei Doi

Discussion

Loading...

Member takes

Overview

Review reveals critical mortality in patients with carbapenem-resistant Acinetobacter baumannii, highlighting urgent need for infection control and therapeutic strategies.

Key Points

  • Carbapenem-resistant Acinetobacter baumannii has a mortality rate exceeding 20%, particularly in bloodstream infections.
  • The organism is endemic in many regions, contributing to over 50,000 deaths annually worldwide.
  • Horizontal gene transfer facilitates the global spread of resistance genes among epidemic clones in healthcare settings.
  • Despite its significant public health threats, treatment options for CRAb remain limited, underscoring the need for new therapeutics.

Cite This Study

Boutzoukas et al. (2025) studied this question.

synapsesocial.com/papers/68c23e94b210217d64792953https://doi.org/10.1093/jacamr/dlaf134
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Carbapenem-Resistant Acinetobacter baumannii: Virulence Factors, Molecular Epidemiology, and Latest Updates in Treatment Options2025 · 33 citations
  2. 2Drug-resistant 2025 · 41 citations
  3. 3P27 Carbapenem-resistant <i>Acinetobacter baumannii</i> : a challenge in the intensive care units2025
  4. 4Escalating threat of <i>Acinetobacter baumannii</i>: Resistance mechanisms and mitigation strategies a perspective2025
  5. 5Comparative genomics of carbapenem-resistant <i>Acinetobacter baumannii</i> isolated from pediatric patients in a tertiary care hospital2025